NeuroMetrix to Target Chronic Knee Pain with Quell® 2.0 Wearable Pain Relief Device
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has
launched a marketing initiative focusing on chronic knee
pain. This effort includes direct-to-consumer digital
marketing as well as informing physicians and other health care
providers about the use of Quell for their patients with knee pain.
About one-quarter of U.S. adults suffer from frequent knee pain,
which limits function, decreases mobility, impacts sleep and
reduces quality of life. Chronic knee pain is typically
treated with oral non-steroidal anti-inflammatory drugs and
occasionally prescription opioids. These medications have side
effects and, in the case of opioids, may lead to addiction.
Surgery is an effective option for some individuals with
chronic knee pain.
Transcutaneous electrical nerve stimulation (TENS) is a safe,
non-invasive pain relief option, that has been used by physicians,
physical therapists, and other health care professions for decades
to treat chronic pain. Quell is the only true wearable TENS
device. It is well suited to chronic knee pain because it is
worn just below the knee, is not much larger than a credit card,
and is comfortable enough to use 24/7. Quell is the only TENS
device with specific FDA 510(k) clearance for use while
sleeping. According to the Company’s Quell Health Cloud™,
regular Quell users with knee pain wear their device for 10 hours a
day and 40% use it while sleeping.
Quell has been commercially available over-the-counter since
2015. The most recent version, Quell 2.0, was launched in
late 2018 and represents the most advanced TENS technology on the
market. Key features include:
- Only TENS device powered by a proprietary neurostimulation
- Prescription strength nerve stimulation
- Therapy Autopilot™ automatically controls and personalizes
- Advanced power management requires battery recharging only once
or twice a week
- Controlled and enhanced by the industry leading Quell Relief
- Detects and compensates for changes in the weather that may
- Digital health enabled – objectively tracks sleep, activity and
gait and user reported pain
- Covered by 14 U.S. patents
Quell is available to consumers at QuellRelief.com.
Veterans may obtain Quell through their VA hospital (contact
firstname.lastname@example.org for information).
About NeuroMetrix NeuroMetrix is a
leading developer and manufacturer of diagnostic and therapeutic
neurostimulation-based medical devices that are used throughout the
world. The Company has three FDA cleared commercial products.
DPNCheck® is a point-of-care test that is used to evaluate
peripheral neuropathies. ADVANCE™ is a point-of-care device
that provides nerve conduction studies as an aid in diagnosing and
evaluating patients suspected of having focal or systemic
neuropathies. Quell® 2.0 is a wearable, mobile app
enabled, neurostimulation device indicated for symptomatic relief
and management of chronic pain and is available over-the-counter.
The Company maintains an active, industry-leading R&D program.
For more information, visit NeuroMetrix.com.
Thomas T. Higgins, 781-314-2761SVP and Chief Financial
Source: NeuroMetrix, Inc.
A photo accompanying this announcement is available at
Historical Stock Chart
From Aug 2020 to Sep 2020
Historical Stock Chart
From Sep 2019 to Sep 2020